- Home
- STK vs ORGO Comparison
STK vs ORGO Comparison
Compare STK & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- ORGO
- Stock Information
- Founded
- STK 2009
- ORGO 1985
- Country
- STK United States
- ORGO United States
- Employees
- STK N/A
- ORGO N/A
- Industry
- STK Investment Managers
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- ORGO Health Care
- Exchange
- STK Nasdaq
- ORGO Nasdaq
- Market Cap
- STK 614.2M
- ORGO 620.3M
- IPO Year
- STK N/A
- ORGO N/A
- Fundamental
- Price
- STK $36.11
- ORGO $4.02
- Analyst Decision
- STK
- ORGO Buy
- Analyst Count
- STK 0
- ORGO 3
- Target Price
- STK N/A
- ORGO $7.33
- AVG Volume (30 Days)
- STK 38.2K
- ORGO 819.3K
- Earning Date
- STK 01-01-0001
- ORGO 11-06-2025
- Dividend Yield
- STK 6.60%
- ORGO N/A
- EPS Growth
- STK N/A
- ORGO N/A
- EPS
- STK N/A
- ORGO N/A
- Revenue
- STK N/A
- ORGO $429,531,000.00
- Revenue This Year
- STK N/A
- ORGO $2.51
- Revenue Next Year
- STK N/A
- ORGO $25.45
- P/E Ratio
- STK N/A
- ORGO N/A
- Revenue Growth
- STK N/A
- ORGO N/A
- 52 Week Low
- STK $24.95
- ORGO $2.61
- 52 Week High
- STK $34.31
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- STK 68.94
- ORGO 36.21
- Support Level
- STK $35.55
- ORGO $4.02
- Resistance Level
- STK $36.81
- ORGO $4.40
- Average True Range (ATR)
- STK 0.61
- ORGO 0.23
- MACD
- STK -0.03
- ORGO -0.05
- Stochastic Oscillator
- STK 66.43
- ORGO 3.83
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.